These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19802025)

  • 1. A modified comorbidity index for hematopoietic cell transplantation.
    DeFor TE; Majhail NS; Weisdorf DJ; Brunstein CG; McAvoy S; Arora M; Le CT
    Bone Marrow Transplant; 2010 May; 45(5):933-8. PubMed ID: 19802025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
    Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
    Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
    Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
    Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant.
    Wood W; Deal A; Whitley J; Sharf A; Serody J; Gabriel D; Shea T
    Pediatr Blood Cancer; 2011 Sep; 57(3):499-505. PubMed ID: 21384538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation.
    Kagoya Y; Kataoka K; Nannya Y; Kurokawa M
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):394-400. PubMed ID: 20655388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
    Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation.
    Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
    Am J Hematol; 2013 Jun; 88(6):497-502. PubMed ID: 23536204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
    Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
    J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].
    Fujimaki K; Sakai R; Fujisawa S; Fujita H; Tanaka M; Hagihara M; Koharazawa H; Miyazaki T; Tomita N; Kanamori H; Maruta A; Ishigatsubo Y
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):87-91. PubMed ID: 18195534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS; Challa TR; Mulrooney DA; Baker KS; Burns LJ
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.
    Kurosawa S; Fukuda T; Tajima K; Saito B; Fuji S; Yokoyama H; Kim SW; Mori S; Tanosaki R; Heike Y; Takaue Y
    Am J Hematol; 2009 Dec; 84(12):815-20. PubMed ID: 19899134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
    Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
    Coffey DG; Pollyea DA; Myint H; Smith C; Gutman JA
    Bone Marrow Transplant; 2013 Sep; 48(9):1253-6. PubMed ID: 23503530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.